☆ 4.7 Meeting Abstract

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA

JOURNAL OF CLINICAL ONCOLOGY (2022)

Get Full Text
Add to Collection

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 4, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.2022.40.4_suppl.379

Keywords

-

Categories

Oncology

Funding

  1. AstraZeneca

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.